Good news!
"ViroBlock, a Jerusalem-based startup, has developed a new drug platform for rapidly generating antiviral drugs that target proteins common to all Covid-19 variants and other viruses, including influenza, Zika, West Nile and hepatitis. ...
The platform targets the E (for “envelope”) protein in a virus, which are 95% alike, no matter the virus. ...
ViroBlock also inhibits a separate protein, 3a, present in most viruses. ...
ViroBlock was founded in 2020 through Yissum, the Hebrew University technology transfer company. ..."
The platform targets the E (for “envelope”) protein in a virus, which are 95% alike, no matter the virus. ...
ViroBlock also inhibits a separate protein, 3a, present in most viruses. ...
ViroBlock was founded in 2020 through Yissum, the Hebrew University technology transfer company. ..."
No comments:
Post a Comment